Department of Thyroid & Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
Department of Gynecology and Obstetrics, Paropakar Maternity and Women's Hospital, Kathmandu 00977, Nepal.
Anticancer Agents Med Chem. 2021;21(18):2520-2524. doi: 10.2174/1871520621666210126093630.
Breast cancer (BC) is increasingly becoming the primary reason for death in women, which sounded the alarm. Thus, finding a novel management target for BC is imminent.
The data of gene expression and clinicopathological characteristics were downloaded from The Cancer Genome Atlas (TCGA). The expression of nuclear receptor co-activator 5 (NCOA5) in 35 paired breast cancer and adjacent tissues was measured by quantitative real-time polymerase chain reaction (qRT-PCR). Univariate and Multivariate logistic regression methodology was applied to analyze the prognostic factors for lymph node metastasis (LNM). Based on the status of breast cancer-relative receptors, patients were distributed in six groups, then the Kaplan-Meier survival analysis with log-rank test was applied to investigate the involvement among the expression of NCOA5 and overall survival (OS).
The expression of NCOA5 in BC was greater than normal tissues when comparing the data from TCGA. This result had also been verified in our local cohort. The expression of NCOA5 was closely related to LNM, Estrogen receptor (ER) status and progesterone receptor (PR) status. The consequence of Multivariate logistic regression analysis showed that the expression of NCOA5, tumor size, ER status and clinical stage was significantly associated with LN. Moreover, subgroup analyses showed that high expression of NCOA5 is an independent risk factor for OS in patients who were in ER (+) or PR (+) or maybe human epidermal growth factor receptor-2(Her-2) positive status.
NCOA5 was significantly correlated with LNM in BC. Meanwhile, the expression of NOCA5 could predict the OS time, especially in breast cancer patients whose status of hormone receptor was positive. NCOA5 may act as a promising treatment target to shortening the treatment period and improving the prognosis of ER (+) breast cancer.
乳腺癌（BC）的发病率在女性中日益增高，且成为导致女性死亡的首要原因，这敲响了警钟。因此，寻找治疗乳腺癌的新靶点迫在眉睫。
从癌症基因组图谱（TCGA）中下载基因表达和临床病理特征数据。采用实时荧光定量聚合酶链反应（qRT-PCR）测量 35 对乳腺癌及相邻组织中核受体共激活因子 5（NCOA5）的表达。采用单因素和多因素逻辑回归方法分析淋巴结转移（LNM）的预后因素。根据乳腺癌相关受体的状态，将患者分为六组，然后应用 Kaplan-Meier 生存分析和对数秩检验研究 NCOA5 表达与总生存（OS）之间的关系。
TCGA 数据显示，BC 中 NCOA5 的表达高于正常组织。这一结果在我们的本地队列中也得到了验证。NCOA5 的表达与 LNM、雌激素受体（ER）状态和孕激素受体（PR）状态密切相关。多因素逻辑回归分析的结果表明，NCOA5 的表达、肿瘤大小、ER 状态和临床分期与 LN 显著相关。此外，亚组分析表明，NCOA5 的高表达是 ER（+）、PR（+）或人表皮生长因子受体-2（Her-2）阳性状态患者 OS 的独立危险因素。
NCOA5 与 BC 中的 LNM 显著相关。同时，NOCA5 的表达可以预测 OS 时间，特别是在激素受体阳性的乳腺癌患者中。NCOA5 可能成为一种有前途的治疗靶点，以缩短治疗周期，改善 ER（+）乳腺癌的预后。
